ライフサイエンスコーパス: leucopenia

1 MPN, or TPMT activity and the development of leucopenia.

2 [62%] of 282 patients in the placebo group), leucopenia (106 [38%] vs 82 [29%]), anaemia (53 [19%] vs

3 3%]), hypertension (nine [13%] vs 11 [16%]), leucopenia (12 [17%] vs 13 [19%]), and fatigue (17 [24%]

4 nation treatment and monotherapy groups were leucopenia (121 [74%] of 164 vs 55 [34%] of 164), lympho

5 on, thrombocytopenia (30 [18%] vs 23 [28%]), leucopenia (13 [8%] vs nine [11%]), and anaemia (14 [8%]

6 ia (29 patients), lymphopenia (16 patients), leucopenia (13 patients), and thrombocytopenia (ten pati

7 apy: 136 (75%) of 181 patients had grade 3-4 leucopenia, 148 (82%) had grade 3-4 neutropenia, 19 (10%

8 4%] of 67 patients in the comparator group), leucopenia (16 [23.5%] vs five [7.5%]), and thrombocytop

9 ] of 113 patients), vomiting (22 [19%]), and leucopenia (17 [15%]).

10 of 113 patients), vomiting (22 [19.5%]), and leucopenia (17 [15.0%]) in the gemcitabine and cisplatin

11 3 events during induction chemotherapy were leucopenia (17 [39%]) and neutropenia (five [11%]), and

12 46 [18%]), neutropenia (19 [7%] vs 24 [9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%]

13 febrile neutropenia (57 [18%] vs 34 [11%]), leucopenia (22 [7%] vs 17 [6%]), decreased neutrophil co

14 were neutropenia (59 [23%] of 259 patients), leucopenia (27 [10%]), and decreased white blood cell co

15 ies-namely, anaemia (in nine [9%] patients), leucopenia (30 [29%]), neutropenia (48 [46%]), and throm

16 Leucopenia (30 patients vs four patients) and thrombocyt

17 d include anemia (22% required transfusion), leucopenia (34%, grade 3 to 4), and mucositis (84%, grad

18 were neutropenia (78 [30%] of 262 patients), leucopenia (42 [16%]), and decreased neutrophil count (4

19 rombocytopenia (67 [27%] vs three [2%]), and leucopenia (46 [19%] vs three [2%]).

20 were neutropenia (937 events vs 797 events), leucopenia (507 vs 362), and lethargy (456 vs 272).

21 penia (133 [41%] of 327 vs 62 [19%] of 329), leucopenia (57 [17%] vs 22 [7%]), hypertension (46 [14%]

22 rile neutropenia (112 [5%] vs 142 [6%]), and leucopenia (62 [3%] vs 61 [3%]).

23 ] of 169 patients in the trastuzumab group), leucopenia (64 [19%] vs 34 [20%]), and diarrhoea (60 [18

24 73) and the most common grade 4 toxicity was leucopenia (68 [93%] of 73).

25 6 [38%]) anaemia (76 [11%] vs 40 [12%]), and leucopenia (81 [12%] vs 35 [10%]).

26 n grade 3-4 adverse events were neutropenia, leucopenia (857 [30.2%] vs three [0.1%]), and fatigue (6

27 s 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35

28 oup), anaemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).

29 ifosfamide than with doxorubicin alone-were leucopenia (97 [43%] of 224 patients vs 40 [18%] of 223

30 One patient developed leucopenia after 4 days of treatment; counts returned to

31 Grade 4 leucopenia and grade 3 or 4 anemia presented 2.5 times m

32 there is a corresponding increase in splenic leucopenia and immune suppression.

33 als' survival (20 days), with only transient leucopenia and thrombocytopenia but no overt toxicity.

34 biomarkers of complement activation, reduced leucopenia and thrombocytopenia, and lowered the accumul

35 ted with a significantly higher incidence of leucopenia and thrombocytopenia.

36 es manifested by thrombocytopenia, transient leucopenia, and aggressive disseminated intravascular co

37 verse events being thrombocytopenia, anemia, leucopenia, and fatigue.

38 never clinical features such as hypotension, leucopenia, and fever are noted in patients with suspect

39 leukemic transformation or severe anemia and leucopenia as a result of progressive MDS.

40 bo group), fatigue (four [13%] vs two [6%]), leucopenia (five [16%] vs three [9%]), neutropenia (10 [

41 61.4%, 22.4%, and 23.8% experienced, grade 4 leucopenia, grade 3 or 4 anemia, and grade 3 or 4 thromb

42 %]; group C: 5 [5%]; group D: 15 [16%]), and leucopenia (group A: 13 [12%]; group B: 6 [6%]; group C:

43 [<1%]; HEC-2: seven [3%] vs two [<1%]), and leucopenia (HEC-1: six [2%] vs two [<1%]; HEC-2: two [<1

44 (1%) of 77 patients in the letrozole group, leucopenia in 16 (19%) versus none, and fatigue in four

45 (5%) were: neutropenia in 37 patients (80%); leucopenia in 25 patients (54%); fatigue in 23 patients

46 ere or life-threatening mucositis in 57% and leucopenia in 65% of patients.

47 Cytomegalovirus (CMV)-associated leucopenia in heart transplant patients is poorly charac

48 ients, neutropenia in ten (1%) patients, and leucopenia in nine (1%) patients.

49 The absence of leucopenia in subclinical late infections is a new impor

50 ajor toxicity (WHO grade 3 and 4), including leucopenia, nausea, infection, and others, was documente

51 ion treatment; the most frequent events were leucopenia, neutropenia, and fatigue.

52 erlipidemia, elevated transaminases, anemia, leucopenia, neutropenia, and mucositis.

53 mparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.

54 8%] of 111 patients), fatigue (14 [13%]) and leucopenia (nine [8%]) were the most common chemotherapy

55 ee [12%] vs 0), fatigue (one [4%] each), and leucopenia (one [4%] each).

56 loblastic anaemia, mild thrombocytopenia and leucopenia, sensorineural deafness and diabetes mellitus

57 nts), lymphopenia (ten), neutropenia (nine), leucopenia (seven), and anaemia (five).

58 [14%]), febrile neutropenia (six [12%]), and leucopenia (six [12%]).

59 e (eight [17%] and two [10%], respectively), leucopenia (six [13%] and three [14%], respectively), pn

60 ue (eight [5%]), neutropenia (six [4%]), and leucopenia (six [4%]) in those assigned to chemotherapy.

61 tients), lymphopenia (24), neutropenia (17), leucopenia (ten), anaemia (seven), and diarrhoea (five).

62 , has adverse effects including neutropenia, leucopenia, thrombocytopenia, anemia, fatigue and nausea

63 or bone marrow-related complication (grade 4 leucopenia was noted in six patients, grade 4 lymphopeni

64 spiratory tract infection (p = 0.003) and no leucopenia were seen in the Everolimus group.